These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35800545)

  • 1. Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India.
    Bansal Y; Chand P; Bansal N; Singh P
    J Family Med Prim Care; 2022 May; 11(5):2201-2206. PubMed ID: 35800545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholera and COVID-19 pandemic prevention in multiple hotspot districts of Uganda: vaccine coverage, adverse events following immunization and WASH conditions survey.
    Bwire G; Kisakye A; Amulen E; Bwanika JB; Badebye J; Aanyu C; Nakirya BD; Okello A; Okello SA; Bukenya JN; Orach CG
    BMC Infect Dis; 2023 Jul; 23(1):487. PubMed ID: 37479986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccination: Is it a matter of concern?
    Kushwaha P; Pundhir A; Gahlot A
    J Family Med Prim Care; 2022 Jun; 11(6):2431-2436. PubMed ID: 36119229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India.
    Parida SP; Sahu DP; Singh AK; Alekhya G; Subba SH; Mishra A; Padhy BM; Patro BK
    J Med Virol; 2022 Jun; 94(6):2453-2459. PubMed ID: 35149993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India.
    Chakraborty A; Reval N; Kamath L
    Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A First Report on Side-Effects of COVID-19 Vaccines among General Population in Sudan: A Cross-Sectional Analysis.
    Mohamed MS; Mohamed AO; Alenazy R; Khan YH; Idriss MT; Alhudaib NAA; Elsaman T; Mohamed MA; Eltayib EM; Mallhi TH
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccine Hesitancy: The Perils of Peddling Science by Social Media and the Lay Press.
    Thorakkattil SA; Abdulsalim S; Karattuthodi MS; Unnikrishnan MK; Rashid M; Thunga G
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To Study Adverse Effect following Immunization (AEFI) and COVID-19 Infection amongst COVID-19 Vaccine Benefeciaries.
    N PP; S CS; F JV; B AB; A KM; T DP; N GC; R IA
    J Assoc Physicians India; 2022 Feb; 70(2):11-12. PubMed ID: 35436817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Adverse Events Following COVID-19 Vaccination: A Cross-sectional Study in Ibadan, Nigeria.
    Alao MA; Ogunbosi BO; Ibrahim OR; Oladokun RE; Lagunju IA
    Niger Med J; 2022; 63(3):248-258. PubMed ID: 38835530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.
    Hills SL; Soeung SC; Sarath S; Morn C; Dara C; Fischer M; Thigpen MC
    PLoS One; 2022; 17(6):e0269480. PubMed ID: 35679297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine hesitancy: Beliefs and barriers associated with COVID-19 vaccination among Egyptian medical students.
    Saied SM; Saied EM; Kabbash IA; Abdo SAE
    J Med Virol; 2021 Jul; 93(7):4280-4291. PubMed ID: 33644891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events following COVID-19 immunisation (AEFI) at a COVID-19 vaccination centre: An observational analytical study.
    Shukla V; Sachan B; Jauhari S; Bhardwaj S; Pathak A; Kandpal SD
    J Family Med Prim Care; 2023 Mar; 12(3):460-465. PubMed ID: 37122665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine Safety: Assessing the Prevalence and Severity of Adverse Events Following COVID-19 Vaccination amongst Healthcare Workers in Tertiary Health Facilities in Nigeria.
    Azees AS; Fasiku MM; Isa A; Ezenwoko AZ; Ahmed A; Temitayo-Oboh AO; Utulu R; Adeniyi MA; Musa A; Alo C; Ibrahim UM; Imhonopi GB; Adesoye OO; Okeke IM; John GT; Ayinla AY
    Niger Postgrad Med J; 2024 Jan; 31(1):1-7. PubMed ID: 38321791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel.
    Hidayat R; Mustika AP; Avisha F; Djuliannisaa Z; Winari DD; Putri RA; Lisman HM; Davin V; Widhani A; Aini MH; Rahmadani M; Istanti ND; Giantini A
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study.
    Velhal GD; Kamath YV; Agrawal AS; Vora DS; Dwivedi VR
    Indian J Community Med; 2022; 47(4):613-617. PubMed ID: 36742958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India.
    Kamble B; Bashar MA; Mishra CP
    Cureus; 2022 Feb; 14(2):e21848. PubMed ID: 35273834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.